First Patient Treated In Bioniche Phase III Refractory Bladder Cancer Trial
Thu, 09 Nov 2006 08:00 AM EST
... Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced the entry of the first patient in its Phase III trial for refractory bladder cancer. The patient was treated by Dr. Gary Steinhoff, Dr. Steinhoff Clinical Research, Victoria, British Columbia, Canada. The U.S. [click link for full article] ...
Related Topics
- Clinical Trials
- Bladder Cancer
- Patient Issues
- Bladder
- Gallbladder Cancer
- Antithrombin III
- Pancreatic Cancer
- Overactive Bladder
- Cancers
- Infection (bladder)
- Gallbladder Diseases
- Kidney Cancer
- Bladder Diseases
- Bladder Control
- Personal Medical Records
- Ovarian Cancer
- Cancer Alternative Therapy
- Metastatic Cancer
- Tarceva
- Familial Dysautonomia

Not Signed In -


